Multiple Sclerosis Patients Saw Improvements With NAC

A 2026 study linked N-acetylcysteine treatment to reduced pain and improved cognition in patients.

Updated on Oct. 13, 2026 in Stroke

Multiple Sclerosis Patients Saw Improvements With NAC

Live Poll

Would you trust a non-prescription antioxidant supplement as a complement to your medical treatment plan?

In a study reported in 2026, researchers observed significant improvements in pain, fatigue, and cognition among multiple sclerosis patients treated with N-acetylcysteine. The findings provided insights into how the antioxidant might impact brain connectivity and glucose metabolism over a four-month period.

Why it matters

The study investigated N-acetylcysteine as a potential way to address oxidative stress, which is a known driver of neurodegeneration in multiple sclerosis patients. These results offer a potential new avenue for managing complex symptoms that currently affect millions of individuals.

The study utilized a randomized sample of 36 patients, with the treatment group receiving a weekly 50 mg/kg intravenous dose and 500 mg of oral N-acetylcysteine twice daily. Statistical significance was noted for pain, fatigue, cognition, and attention improvements.

The players

Thomas Jefferson University

This academic institution based in Philadelphia served as the research site for the clinical study.

IBRO Neuroscience Reports

This peer-reviewed publication served as the outlet for the study findings.

The details

Researchers used an integrated PET-MRI platform with resting BOLD fMRI and FDG PET to measure connectivity alterations in the inferior frontal region, cerebellum, and parts of the temporal and parietal lobes. Participants completed standardized questionnaires to track clinical changes in their daily symptoms throughout the study.

The study findings were published and reported in 2026.
Patients underwent treatment and observation for a duration of 4 months.

The Big Picture

This study contributes to the historical research on neurodegeneration driven by oxidative stress in multiple sclerosis. It marks a shift by providing concrete neuroimaging data that links metabolic changes to the symptom relief reported by patients.

This study provides early evidence that N-acetylcysteine may offer a new option for managing chronic pain and cognitive fatigue in patients. Individuals should consult their primary neurologist before making changes to their care plan or starting new supplements.

The takeaway

These findings represent a significant step in identifying non-invasive interventions for neurodegeneration in multiple sclerosis. Patients may find hope in the potential for addressing both metabolic and clinical symptoms through antioxidant-based treatments.

What happens next

Researchers are planning future studies to determine the appropriate long-term dosing regimens, the total duration of effective treatment, and the optimal timing for starting this therapy in multiple sclerosis patients.